logo-loader

Tissue Regenix Group chief hopes US DermaPure deal is first of many

Published: 15:46 01 Jul 2016 BST

Chief executive of medtech group Tissue Regenix Group PLC (LON:TRX) Antony Odell talks to Proactive  about the significance of a three year contract won with a national US group purchasing organisation (GPO) for its skin graft product DermaPure.

The deal spans 43 states, with the GPO's membership including more than 800 acute care hospitals, 186 different Health Systems and more than 1,000 long-term care facilities.

"These GPOs are particularly important because they represent economic gateways on behalf  of a wide range of different care settings. This is a very early sign of first success in this space. We are making long term investments into the US market and this is just the first we hope to achieve."

Odell added that he hoped to achieve further progress on sign-ups over the next 18 months.

Tissue Regenix unveils growth strategy and positive EBITDA milestone

Tissue Regenix Group PLC (AIM:TRX) CEO Danny Lee and CFO David Cocke discussed the company's 2023 operational and financial performance in an interview with Proactive's Stephen Gunnion. Tissue Regenix is a global leader in regenerative medicine, focusing on tissue-based scaffold technologies...

1 week, 2 days ago